Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2722)	1/29/2001 9:50:41 PM
From: aknahow	of 52153

Peter thanks. The referenced reply was also helpful. Since I had not heard of Onyx, or not remembered anything, I was wondering if Onyx-015 had any real promise or not. When the experts at S.I. are silent about something I take it as a bad sign. This brings us to your question.<g> Xoma has signed cell expression technology agreements with over 20 companies. Its filings with the SEC have left open the possibility that one type of agreement it might make could be manufacturing. Xoma was selected by DNA to run its' P I & II clinical trials. It is not clear if they are running the P III psoriasis trial or not. DNA may have taken this back in house. XOMA got 25% of gross profits of anti-cd11a for its' collaboration with DNA. Running a trial and producing a drug are not identical but they are contract services and thus IMO related. I did not mention XOMA, originally and it was not stealth hype.<g> I had a real need to know if the agreement with Onyx was important or not. My read, for now, is that it is important.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next